[go: up one dir, main page]

NO964950D0 - Krystallinsk hydroklorid av (R)-(-)-2-æN-[4-1,1-dioksido-3-okso-2,3-dihydrobenzisotiazol-2-yl)-butylÅ-aminometylå-chroman - Google Patents

Krystallinsk hydroklorid av (R)-(-)-2-æN-[4-1,1-dioksido-3-okso-2,3-dihydrobenzisotiazol-2-yl)-butylÅ-aminometylå-chroman

Info

Publication number
NO964950D0
NO964950D0 NO964950A NO964950A NO964950D0 NO 964950 D0 NO964950 D0 NO 964950D0 NO 964950 A NO964950 A NO 964950A NO 964950 A NO964950 A NO 964950A NO 964950 D0 NO964950 D0 NO 964950D0
Authority
NO
Norway
Prior art keywords
dihydrobenzisothiazol
dioxido
ene
oxo
butyl
Prior art date
Application number
NO964950A
Other languages
English (en)
Other versions
NO964950L (no
NO307340B1 (no
Inventor
Alfons Grunenberg
Oliver Brehm
Michael Conrad
Dietrich Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO964950D0 publication Critical patent/NO964950D0/no
Publication of NO964950L publication Critical patent/NO964950L/no
Publication of NO307340B1 publication Critical patent/NO307340B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO964950A 1995-11-22 1996-11-21 Krystallinsk hydroklorid av (R)-(-)-2-{N-[4-(1,1-dioksido-3- okso-2,3-dihydro-benzisotiazol-2-yl)-butyl]-aminometyl}-kroman, legemiddel inneholdende samme, samt fremstilling og anvendelse av samme NO307340B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (3)

Publication Number Publication Date
NO964950D0 true NO964950D0 (no) 1996-11-21
NO964950L NO964950L (no) 1997-05-23
NO307340B1 NO307340B1 (no) 2000-03-20

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964950A NO307340B1 (no) 1995-11-22 1996-11-21 Krystallinsk hydroklorid av (R)-(-)-2-{N-[4-(1,1-dioksido-3- okso-2,3-dihydro-benzisotiazol-2-yl)-butyl]-aminometyl}-kroman, legemiddel inneholdende samme, samt fremstilling og anvendelse av samme

Country Status (32)

Country Link
US (1) US5830908A (no)
EP (1) EP0775704B1 (no)
JP (1) JPH09143180A (no)
KR (1) KR970027079A (no)
CN (1) CN1086703C (no)
AR (1) AR004961A1 (no)
AT (1) ATE201872T1 (no)
AU (1) AU712922B2 (no)
BR (1) BR9605646A (no)
CA (1) CA2190700A1 (no)
CZ (1) CZ289730B6 (no)
DE (2) DE19543478A1 (no)
DK (1) DK0775704T3 (no)
EE (1) EE9600183A (no)
ES (1) ES2159342T3 (no)
GR (1) GR3036505T3 (no)
HU (1) HUP9603237A3 (no)
IL (1) IL119647A (no)
MX (1) MX9605741A (no)
MY (1) MY132473A (no)
NO (1) NO307340B1 (no)
NZ (1) NZ299780A (no)
PL (1) PL317090A1 (no)
PT (1) PT775704E (no)
RU (1) RU2181723C2 (no)
SG (1) SG44989A1 (no)
SI (1) SI0775704T1 (no)
SK (1) SK150096A3 (no)
TR (1) TR199600930A2 (no)
TW (1) TW449595B (no)
UA (1) UA45338C2 (no)
ZA (1) ZA969753B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748182A (en) * 1986-03-05 1988-05-31 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
TW449595B (en) 2001-08-11
ATE201872T1 (de) 2001-06-15
ES2159342T3 (es) 2001-10-01
CA2190700A1 (en) 1997-05-23
MY132473A (en) 2007-10-31
EE9600183A (et) 1997-06-16
AU712922B2 (en) 1999-11-18
PT775704E (pt) 2001-09-28
AU7177296A (en) 1997-05-29
RU2181723C2 (ru) 2002-04-27
HU9603237D0 (en) 1997-01-28
CZ342896A3 (en) 1997-06-11
EP0775704A1 (de) 1997-05-28
NZ299780A (en) 1998-09-24
KR970027079A (ko) 1997-06-24
UA45338C2 (uk) 2002-04-15
ZA969753B (en) 1997-03-25
BR9605646A (pt) 1998-08-18
EP0775704B1 (de) 2001-06-06
CN1086703C (zh) 2002-06-26
DK0775704T3 (da) 2001-07-23
HUP9603237A2 (hu) 1998-01-28
DE59607040D1 (de) 2001-07-12
NO964950L (no) 1997-05-23
MX9605741A (es) 1997-05-31
IL119647A0 (en) 1997-02-18
TR199600930A2 (tr) 1997-06-21
IL119647A (en) 1999-12-22
NO307340B1 (no) 2000-03-20
SG44989A1 (en) 1997-12-19
CZ289730B6 (cs) 2002-03-13
GR3036505T3 (en) 2001-11-30
DE19543478A1 (de) 1997-05-28
US5830908A (en) 1998-11-03
HUP9603237A3 (en) 1998-12-28
JPH09143180A (ja) 1997-06-03
SI0775704T1 (en) 2001-08-31
AR004961A1 (es) 1999-04-07
PL317090A1 (en) 1997-05-26
SK150096A3 (en) 1997-08-06
CN1152574A (zh) 1997-06-25

Similar Documents

Publication Publication Date Title
NO964950D0 (no) Krystallinsk hydroklorid av (R)-(-)-2-æN-[4-1,1-dioksido-3-okso-2,3-dihydrobenzisotiazol-2-yl)-butylÅ-aminometylå-chroman
PT846422E (pt) Formula infantil anti-regurgitacao
DE69621026D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
IT1289532B1 (it) Composti, di cloridrato di paroxetina e procedimenti per la loro preparazione
NO306783B1 (no) Fremgangsmåte for fremstilling av 1-(2'-deoksy-2',2'-difluor-D-ribofuranosyl-4-aminopyrimidin-2-on)hydroklorid
DE69606721D1 (de) 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
NO961966D0 (no) Fremgangsmåte for korrigering av avviksregistrering
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
FI954632A0 (fi) Korrigering av stoetbreddning hos icke-dispersiv absorptionsmaetning av gasar
NO982237D0 (no) Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO975220L (no) Ny fremgangsmåte for fremstilling av ropivacainhydrokloridmonohydrat
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
NO20003145D0 (no) FremgangsmÕte for fremstilling av paroxetine-hydroklorid
FI953319A0 (fi) Dimetyylinaftaleenin valmistus
BR9610514A (pt) Inibidores cicloantihelmínticos
DE69610440D1 (de) Phenylacetamid-derivate
FI950686L (fi) Anordning foer oeverfoering av spillvaermo till jordenergipumpeno jordkrets
FI955924A0 (fi) Rengoering av skivvaermevaexlare med effektultraljud
FIU950441U0 (fi) Glasfoeremaol med bihang av metalltraod
FI952808A0 (fi) Rensapparat foer invaendig rengoering av luftkanaler med rektangulaert tvaersmitt
DE69600539D1 (de) Wismuth-Blei-Verbindung
IT1281069B1 (it) Preparazione di metossimetilmelammine.
ATA36395A (de) Mehrschaliges mauerwerk
FI2067U1 (fi) Verktyg foer boejning av en flaens
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2003